Remove Antibody Remove Branding Remove Protein
article thumbnail

Strike two for Novartis’ lung cancer antibody canakinumab

pharmaphorum

Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.

Antibody 124
article thumbnail

Current and future players in the lupus market

Pharmaceutical Technology

Additionally, Roche also markets MMF (under the brand name CellCept), an off-label immunosuppressive agent that is commonly prescribed to SLE and LN patients, although generic versions of MMF are also available throughout the 7MM.

Marketing 278
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

Known by the brand name Roctavian, BioMarin’s haemophilia A therapy valoctocogene roxaparvovec could be fairly priced in the range of $1.95–1.96 Haemophilia A is caused by insufficient levels of the clotting protein factor VIII, while patients with haemophilia B lack adequate factor IX levels.

article thumbnail

Blood vessels produce protein that promotes metastases

The Pharma Data

Scientists from the German Cancer research facility (DKFZ) and therefore the Medical Faculty Mannheim, Heidelberg University, have now identified a replacement protein produced by blood vessels that permits tumor cells to metastatically colonize organs.

Protein 52
article thumbnail

New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma

The Pharma Data

Roche today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June.

article thumbnail

Herd immunity won’t stop the outbreak: 3 Dangerous Covid-19 Myths

Find Me Cure

Vandalizing cell towers is not going to get rid of this new virus in the corona family and avoiding certain brands of beer is not a good prevention strategy. . This means that in order for herd immunity to work, 50-70% of the world population needs to get infected and then develop antibodies. .

article thumbnail

GSK’s Benlysta claims first FDA okay for lupus kidney damage

pharmaphorum

Originally approved in 2011 as an IV therapy for adults with SLE, a debilitating autoimmune disease, GSK got a green light for the subcutaneous formulation in 2017 and last year extended the label of the antibody to include paediatric patients aged over five.